LAVAL, QC / ACCESSWIRE / January 30, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its dermatology business, Ortho Dermatologics, today announced the U.S. launch of CABTREO™ (clindamycin ...
LAVAL, QC / ACCESSWIRE / October 20, 2023 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) ("Bausch Health") and its dermatology business, Ortho Dermatologics, today announced that the U.S. Food ...
LAVAL, QC / ACCESSWIRE / November 18, 2024 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE/TSX:BHC), today announced that Pr CABTREO TM (clindamycin phosphate, adapalene and ...
Cabtreo combines clindamycin phosphate, a lincosamide antibacterial, adapalene, a retinoid, and benzoyl peroxide, an oxidizing agent with bactericidal and keratolytic effects, into one topical gel.
CABTREO is the first and only triple-combination topical treatment for acne approved by Health Canada with three mechanisms of action - an antibiotic, a retinoid and an antibacterial agent - to ...
Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (USFDA) for Clindamycin Phosphate Gel USP, 1% (USRLD: Cleocin T Gel, 1%). Clindamycin ...
July 3, 2002 -- The combination of topical clindamycin with benzoyl peroxide is more effective than clindamycin alone at reducing Propionibacterium acnes bacterial counts, according to results of a ...
(MENAFN- GlobeNewsWire - Nasdaq) BRIDGEWATER, N.J., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Solaris Pharma Corporation (“Solaris” or the“Company”) announced today that the Company has received an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback